Update on CML-Like Disorders

Clin Lymphoma Myeloma Leuk. 2020 Sep:20 Suppl 1:S101-S102. doi: 10.1016/S2152-2650(20)30477-8.

Abstract

Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis, clinically heterogeneous entity termed 'BCR-ABL1 negative CML' constituting about 5% of CML cases. Apart from very rare CML cases with cytogenetically cryptic, atypical variant BCR-ABL1 fusions that had been inadvertently missed during the diagnostic work up, most of these cases would now be classified as a subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN), such as atypical CML (aCML), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemia (CNL). A minority would be classified as systemic mastocytosis with associated hematological neoplasm (SM-AHN), myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or with PCM1-JAK2 (MLN-eo), or chronic eosinophilic leukemia not otherwise specified (CEL-NOS).1.

Keywords: Tyrosine kinase fusions; atypical CML; eosinophilia; targeted therapy.

MeSH terms

  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*